Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

Company Overview - Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry, founded in 1996 [2] - The company collaborates with innovators from academic institutions, research hospitals, non-profits, and biopharmaceutical companies, funding innovation directly and indirectly [2] - Royalty Pharma's portfolio includes royalties on over 35 commercial products and 17 development-stage product candidates, such as Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, and others [2] Leadership Appointment - Molly Sawaya has been appointed as Executive Vice President, Head of Human Capital at Royalty Pharma [4] - Molly brings nearly 15 years of HR experience from large global organizations, including Hudson Bay Capital, QBE Insurance Group, Perpetual Limited, and National Australia Bank [1][8] - Her role will focus on fostering a culture of growth and supporting the scaling of the business [8] Business Model - Royalty Pharma funds innovation directly by partnering with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties [2] - Indirectly, the company acquires existing royalties from original innovators, building a portfolio tied to the top-line sales of leading therapies [2]